Jubilant Ingrevia Ltd Q1 FY2024 Concall Summary

Key Takeaways

• Stable quarter, agro headwinds persist: Revenue held steady sequentially despite a 20-25% volume drop in agrochemicals, as pharma and CDMO growth partially offset the decline. Management expects agro destocking to continue for some time.
• Niacinamide recovery drives Nutrition segment: Revenue improved significantly both YoY and sequentially on higher global demand and better price realization, though margins have not yet fully normalized because orders are taken a quarter ahead.
• Diketene ramp-up is the next margin story: Capacity utilization reached 55-60%, and two value-added intermediates were approved for commercialization by year-end, with four more in the approval pipeline. Real margin improvement is 1-1.5 years out.
• Gross margin optically inflated by low acetic acid: Management insists value-wise margins are sustainable, but the 48% percentage is flattered by very low raw material prices and will fluctuate.
• What to watch next quarter: Whether agrochemical destocking shows any sign of easing, the pace of Niacinamide margin normalization, and progress on FSA coal rail transport access.

Agrochemical Destocking: The Dominant Drag

• Volume hit was severe: Agrochemical volumes in Specialty Chemicals fell 20-25% in the quarter, pulling the segment's overall volume down despite 10-11% growth from pharmaceutical customers.
• Double cause, no timeline: Destocking stems from both difficult weather in Brazil, the US and Europe over the last 6-8 months reducing end-demand, and customers normalizing excess inventory they had built anticipating continued China supply disruption. Management gave no specific timeline for revival.
• China dumping compounded the problem: After a period of constrained supply that prompted customers to build inventory, China began dumping excess material, adding price pressure.
• Mix shift underway: Agrochemical share of total revenue fell from 40% to 33%, with pharma and CDMO growing double-digit to offset.
• Customer mix undisclosed: Management declined to break out the proportion of generic vs innovator customers in agrochemical sales, calling it "difficult to give that percentage as of now."

Rajesh Srivastava: "Cost of production, we always claim that we are best in the world. Otherwise, if China does not dump the material, we also get an opportunity to sell in China. It is only when China decides to sell."

Nutrition & Health Solutions: Niacinamide Turns

• Revenue jump was the quarter's bright spot: Significant improvement both YoY and sequentially, driven by higher global demand for Niacinamide and a meaningful improvement in price realization.
• Margin lag is a timing issue: Margins remain below historical levels because orders are booked a quarter in advance; the price improvement only began mid-last quarter, so the full benefit has not yet flowed through. Management says the ongoing and future quarters "should be definitely better."
• Management won't pin a number: When asked if margins should normalize to the 18-20% range in H2, management declined to give a percentage, calling it "very difficult to talk."
• Capacity expansion on track: Capex for a new GMP-compliant facility producing cosmetic and food grade Niacinamide is approved and work is proceeding as planned.

Diketene: The Long Margin Build

• Utilization milestone reached: Diketene capacity utilization has climbed to 55-60%, which management calls a "good achievement" in stabilizing the building-block production.
• Value-added products are the real unlock: Two intermediates were approved for commercialization in the last quarter of the calendar year; another four are expected to come up for approval in the next 2-3 quarters. Over a 1 to 1.5 year horizon, these will begin to lift overall Diketene profitability.
• Volume alone helps, but not enough: Higher utilization of the base Diketene plant will improve EBITDA, but the step-change in margins depends on the downstream value-added pipeline.

Rajesh Srivastava: "Now, here onwards, you can only see the notch way going forward in terms of profitability."

Chemical Intermediates: Price Pressure, Volume Resilience

• Revenue down on pass-through pricing: Lower Acetic Acid prices dragged down realization on both Acetic Anhydride and Ethyl Acetate, reducing revenue YoY.
• Volumes held up on pharma demand: Acetic Anhydride volumes were significantly higher due to demand from pharmaceutical and other non-agro end users; the plant is running at ~80% utilization across three sites.
• Ethyl Acetate rationalization continues: The business is deliberately rationalizing sales due to excess supply, with demand further impacted negatively in the EU and US regions.
• Margin percentage is a mirage: Segment margin percentage improved despite lower realization only because Acetic Acid input prices are at very low levels; absolute value margins were maintained.

Rajesh Srivastava: "But what I said will be maintained is the -- definitely better value. But percentage is very difficult, because right now, you see the acetic acid prices are very, very low level."

Costs & Capex: Coal Relief Is Gradual

• Coal costs are falling, but slowly: Per-ton coal cost has come down ~20-25% YoY, but the aggregate fuel bill has not dropped proportionally because production volumes have grown. Further reduction is expected as coal prices continue to normalize.
• Structural floor on coal prices: Management was explicit that coal prices will never return to 2021 levels because the global coal price structure has permanently shifted.
• FSA coal logistics penalty: FSA coal is being received via road transport rather than rail because the government has not yet opened 100% rail access, keeping costs ~20% above normal rail-based levels. Easing may happen this quarter.
• Capex cadence undisclosed: Management declined to provide quarterly capex update slides that were previously shared, saying it is "better to give that at the end of the year rather than every quarter."
• CDMO plants ramping: GMP and non-GMP CDMO facilities commissioned last quarter are running at high utilization (>50-60%) and ramping as planned.

Leadership Transition

• CEO change effective 1 October 2023: Rajesh Kumar Srivastava superannuates on 30 September after joining Jubilant in 2000 and holding various leadership roles. Deepak Jain, formerly a senior partner at Bain & Company responsible for APAC Advanced Manufacturing and Service Practice, takes over as CEO and MD.

Shyam Bhartia: "Rajesh joined Jubilant in the year 2000, and since then, he has held various leadership positions. He has grown the business and established a very strong leadership team."

Guidance & Commitments

Key Metrics